Wu Tingyao

Inā hoʻohana wale ʻia a hui pū ʻia paha, ʻo Lingzhi (i kapa ʻia ʻo Ganoderma lucidum a i ʻole Reishi) nā hopena o ka hoʻoponopono ʻana i ke koko, hoʻemi i nā hōʻailona kumuhana a hoʻomaikaʻi i nā lipids koko.Eia kekahi, ʻo ka hoʻohana lōʻihi ʻana o Lingzhi ʻaʻole ia e hoʻopilikia i nā hana kino.No nā kikoʻī, e ʻike "Ua hōʻoia nā hoʻokolohua lapaʻau 50 makahiki i hala aku nei e hiki iā Lingzhi ke hoʻomaikaʻi i ka hypertension" a "Ua hōʻoia nā noiʻi lapaʻau e hoʻomaikaʻi ʻo Lingzhi i ke koko kiʻekiʻe akā ʻaʻole pili i ke koko maʻamau".

Eia naʻe, ʻaʻole ʻo Lingzhi wale nō nā pono i luna no ka hypertension akā hoʻomaikaʻi pū i ka viscosity koko, microcirculation (ke koko o nā capillaries), ke koko koko a me ka insulin resistance i nā maʻi hypertensive.ʻOiai ʻaʻole pili i ke kahe koko, hiki iā ia ke hoʻoikaika i ka microcirculation a hoʻonui i ke kahe koko i nā kānaka olakino.

Hoʻomaikaʻi ʻo Lingzhi i ke kahe koko i nā maʻi hypertensive me ke koko kiʻekiʻe viscosity.

I ka makahiki 1992, ua paʻi pū ʻo Shanghai Medical University a me Wakan Shoyaku Laboratory Co i kahi hōʻike lapaʻau ma ka "Journal of Chinese Pharmaceutical Sciences", nāna i nānā i nā pono o ka ʻai ʻana i ka Lingzhi i nā poʻe maʻi me nā maʻi cardiovascular a me ka viscosity koko kiʻekiʻe.Ua hoʻāʻo ʻia he 33 mau kumuhana (45 a 86 mau makahiki), a he 17 o lākou i loaʻa i ka hypertension.

Lawe lākou i 2 papa Lingzhi (loaʻa iā 110 mg o Lingzhi hua wai kino wai, e like me 2.75 g Lingzhi hua hua) i kēlā me kēia lā.Ma hope o nā pule he 2, ʻoi aku ka hapa o nā mea i hoʻomaikaʻi i kā lākou mau hōʻailona e like me ke poʻo ʻeha, dazzle, numbness o nā lālā, ka umauma a me ka insomnia;no ka poʻe me ke koko kiʻekiʻe, ua emi ke koko systolic a me ka diastolic e 12.5 mmHg (8.5%) a me 6.4 mmHg (7.2%), ʻo ia ka ʻokoʻa ʻokoʻa ma mua o ka hoʻāʻo (Figure 1).

Hiki ke hoʻopili ʻia ke kahe koko e ka puʻuwai puʻuwai (ka helu o ka manawa o ka puʻuwai e paʻi i kēlā me kēia minuke i ka hoʻomaha) a pili maikaʻi pū ʻia me ka viscosity koko (ke kahe o ke koko).

No ka mea, ʻaʻohe ʻokoʻa koʻikoʻi o nā kumuhana āpau (me ka poʻe me ke koko maʻamau) i ka puʻuwai ma mua a ma hope o ka hoʻāʻo ʻana (74 manawa → 77 manawa), aia lākou a pau ma ke ʻano maʻamau, akā ua hoʻemi nui ʻia ka viscosity koko.No laila, ua manaʻo ʻia ʻo ke kumu e hiki ai iā Lingzhi ke hoʻohaʻahaʻa i ke koko kiʻekiʻe e pili ana i ka hoʻomaikaʻi ʻana i ka viscosity koko.

Hoʻomaikaʻi ʻo Lingzhi i ka paʻakikī e mālama i ke koko kiʻekiʻe a hoʻomaikaʻi pū i ka viscosity koko a me ka microcirculation.

No ka hōʻoia hou ʻana aia kahi pilina ma waena o ka hoʻomaikaʻi ʻana o ke koko kiʻekiʻe e Lingzhi a me ka hoʻomaikaʻi ʻana i ke koko viscosity, ua hoʻohana ka hui mai Shanghai Medical University a me Wakan Shoyaku Laboratory Co, i ka hui pū ʻana me ka Halemaʻi ʻEhā o nā kānaka o Xuzhou City. Hoʻomākaukau ʻo Lingzhi e like me ka haʻawina ma luna aʻe e hana i kahi randomized (hui pū), pālua-makapō (ʻaʻole ʻike nā mea noiʻi a me nā kumuhana i ka hui i hāʻawi ʻia i nā kumuhana) a me ka hoʻāʻo ʻana i ka placebo-controlled clinical test i nā maʻi me ka hypertension refractory.

Wahi a ka pepa a ka mea noiʻi i paʻi ʻia ma "Journal of Chinese Microcirculation" i ka makahiki 1999, ʻo nā "maʻi hypertensive refractory" i komo i ka hoʻokolohua lapaʻau e komo pū ana i nā maʻi me ka hypertension koʻikoʻi i loaʻa i ka mālama ʻana i ka captopril (angiotensin converting enzyme inhibitor) a i ʻole nimodipine (calcium antagonist). ) no hoʻokahi mahina akā ua ʻoi aku ko lākou koko ma mua o 140/90 mmHg.

ʻO ka awelika o nā makahiki o nā kumuhana he 57.8 ± 9.6 mau makahiki, a ʻo ka lakio kāne me ka wahine ma kahi o 2:1.I ka wā o ka hoʻāʻo ʻana, ua lawe nā maʻi i lawe mua i ka lāʻau komohana i ka lāʻau komohana e like me ka mea maʻamau.ʻO ka hui placebo (13 mau hihia) lawe i kahi placebo i kēlā me kēia lā aʻo ka hui Lingzhi (27 mau hihia) lawe i 6 papa Lingzhi i kēlā me kēia lā (i loko o 330 mg Lingzhi fruiting body extract), ua like ia me 8.25 g o Lingzhi fruiting body;ʻO kēia kaʻina he 3 mau manawa ma mua o ka hoʻokolohua lapaʻau i ʻōlelo ʻia i paʻi ʻia ma 1992).

(1) Hoʻomaikaʻi holoʻokoʻa i ke koko
Ma hope o 3 mau mahina o ka hoʻāʻo ʻana, ʻo ke kahe koko o ka hui Lingzhi, inā he aortic blood pressure (ana i ka lima), arteriolar blood pressure (ana ana i ka manamana lima) a i ʻole capillary blood pressure (ana ʻana i ke kui kui-ka ʻili e pili ana i ka lalo. ʻO ka lihi o ke kui a me ka uhi ʻana i ke aʻa o ke kui) he haʻahaʻa loa ma mua o ka hoʻāʻo ʻana, akā ʻaʻohe loli nui i ka hui placebo (Figure 2).

(2) Ua emi pū ka viscosity o ke koko
I ka manawa like, ʻo nā hōʻailona nui no ka loiloi ʻana i ka viscosity koko, e komo pū ana me ke kiʻekiʻe shear rate (wikiwiki kahe wikiwiki) holoʻokoʻa koko viscosity, haʻahaʻa shear rate (slow blood flow speed) holoʻokoʻa koko viscosity a me plasma viscosity e pili ana i ke koko holoʻokoʻa (ke koko. ʻO ka viscosity ma hope o ka wehe ʻana i nā ʻāpana koko, i hoʻopili ʻia e ka ʻike o ka protein, ka momona a me ke kō koko), ua emi nui i ka hui Lingzhi i ka wā i noho ai ka hui placebo ma kahi (Figure 3).